Please ensure Javascript is enabled for purposes of website accessibility

What Biotech Investors Need to Know About GPCRs

By Motley Fool Staff - May 28, 2016 at 9:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Chances are you’ve heard of tons of GPCR-targeting drugs -- the class that accounts for 40% of all prescription drugs -- but do you know how they work?

A single class of medications accounts for 40% of all prescription drugs in indications ranging from cancer to diabetes. Healthcare analysts Kristine Harjes and Max Macaluso discuss the importance of these drugs and some key names to know, in this clip of Industry Focus: Healthcare.

A transcript follows the video.

This podcast was recorded on March 10, 2016, and was released on May 18, 2016.

Kristine Harjes: The first class that we wanted to talk about, I don't know if we've ever actually mentioned these by name on the show, but we've talked about examples of them in abundance, and these are GPCRs. Max, can you take over from here? What exactly are these?

Max Macaluso: Sure. GPCR stands for G-Protein-Coupled Receptor. They're also called serpentine receptors, it's kind of a neat name, only because they're composed of seven helices that kind of line up and down in the cell membrane.

Harjes: So, like a snake?

Macaluso: Like a snake, exactly.

Harjes: Nice.

Macaluso: I mean, they don't really look like that, (laughs) but all of the images that are based on the crystal structures kind of look like that, hence the name.

Harjes: So, if you have your crayon box out, start drawing a snake.

Macaluso: Exactly. But, they're used for signalling. Essentially, something will bind to the outside of that receptor, outside of the cell, and that causes a reaction within the cell. So, it's kind of like a telegram. Someone knocks on the door, hands a telegram to the person, the person delivers the message. So, they're not actually entering through the door. They just relay a message. That's called the signal cascade

GPCRs are very prevalent throughout the body. They modulate a lot of different biological processes. So, Kristine, for instance, did you have a cup of coffee this morning?

Harjes: I did not, I'm trying to wean myself off of it. But I know plenty of people who did.

Macaluso: (laughs) I certainly did, and I like a little bit of sugar in my coffee, so, the sensation of both bitter and sweet tastes are modulated by GPCRs, as well as other senses like sight and smell. There are also cardiovascular functions, and even certain types of mood, like happiness, are modulated by GPCRs, like serotonin receptors. So, they're very prevalent for a variety of biological processes.

Harjes: So, how exactly are they important to the drug industry?

Macaluso: Well, it might be surprising, but around 30% of prescription drugs currently on the market target a GPCR. So they've been around for a long time, and it's still a very hot area of research. One example is Heptares. This is a GPCR specialist who was recently acquired for around $400 million. There are a number of companies working in this area. And also, just to put this in context, the first crystal structure of a human GPCR won the Nobel Prize in 2012. And that paper was published in 2007. Often, with Nobel Prizes, it could take a couple decades, three or four decades, to be recognized for work. In this case, it was only five years.

So, GPCRs are incredibly important to the drug industry. They'll continue to be. And there are a lot of prominent examples of drugs that target this class of proteins. Zyprexa from Eli Lilly, that treats schizophrenia is an example. You've probably heard of Clarinex as well, that's a popular antihistamine made by Merck, and Zantac, made by Boehringer Ingelheim. Those are three prominent examples.

Harjes: Yeah. To add to that list, because there really are a ton of them, we've got Advair Diskus from GlaxoSmithKline, Abilify, Oxycontin. There are really a ton of these.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.